Revolutionary Cancer Test Shows 62% Accuracy in Screening for Deadly Cancers

Strategic Insights -

A groundbreaking study on the Galleri test, a universal blood test for cancer, has yielded impressive results, showing a 62% accuracy in identifying individuals with cancer. The test, which is being trialled in the NHS, can detect over 50 types of cancer, often before symptoms appear. The Pathfinder 2 study, conducted in the US and Canada, analyzed 23,161 people with no symptoms, and the results suggest that adding Galleri to regular cancer screening programs can lead to a more than seven-fold increase in the number of cancers found within a year.

Key Takeaways:

  • The Galleri test is highly accurate in ruling out cancer in people without the disease, with a 99.6% success rate.
  • Of those people found to have a "cancer signal" detected in their blood, 61.6% went on to be diagnosed with cancer.
  • The test can pinpoint in which organ or tissue the cancer arose, with a 92% accuracy rate.
  • More than half (53.5%) of the new cancers detected by Galleri were at the earliest stage I or II, while more than two-thirds (69.3%) were detected at stages I-III.
  • The test can aid doctors treating patients who may have vague symptoms by helping to direct investigations.
  • Modelling suggests the Galleri test could be effective as an annual blood test in people from the age of 50, when cancer cases begin to rapidly increase.
  • An NHS Galleri trial is expected to be published in the middle of next year, which could lead to the introduction of the test in the NHS.

Statistics:

  • 23,161 people were analyzed in the Pathfinder 2 study, with a follow-up period of at least 12 months.
  • 216 people had a "cancer signal" detected in their blood, with 133 confirmed cancer diagnoses.
  • The likelihood of receiving a cancer diagnosis following a positive test result showing a "cancer signal" was 61.6%.
  • The Galleri test detected a cancer signal in approximately 53.5% of new cancers, with more than 69.3% detected at stages I-III.

Sources:

  • The Galleri test study, presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, no date provided.
  • The study of the Galleri test in the UK NHS, expected to be published in the middle of next year, no date provided.
  • Research published in the journal BMJ Open in May 2022, regarding the effectiveness of an annual blood test for cancer.
  • Quotes from Sir Harpal Kumar, president of International Business and BioPharma at Grail, and other experts in the field of cancer research.